News and Trends 21 Oct 2024 Turning back time with cellular reprogramming: Shift raises $16 million in seed funding As Shift Bioscience raises $16 million in seed funding, delve into the field of cellular reprogramming to tackle age-related diseases. October 21, 2024 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 18 Oct 2024 The AI boom in cancer: Game-changer or just hype? Is AI just hype or a game-changer? Delve into AI’s contribution to oncology, from diagnostics to drug discovery and personalized treatment. October 18, 2024 - 14 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Podcast 18 Oct 2024The future of gene therapy This week, we have a conversation with Michael Parini, CEO of Spur Therapeutics, about the future of gene therapy. October 18, 2024 Share WhatsApp Twitter Linkedin Email Listen Now Apple Music Spotify More
Best in Biotech 17 Oct 2024 Top six European biotech entrepreneurs to know in 2024 (according to VCs) We reached out to VCs to nominate prominent European entrepreneurs in the biotech industry who are committed to bringing potentially life-changing treatments to market. October 17, 2024 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 16 Oct 2024 JAK inhibitors: Are they a good option for treating inflammatory diseases and cancer? Find out more about JAK inhibitors and whether they are a good option for treating inflammatory diseases and cancer. October 16, 2024 - 9 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Sponsored by Angelini Pharma 15 Oct 2024 The future of epilepsy treatment: pioneering advances and patient-centric care Epilepsy, one of the most widespread neurological diseases in the world, characterized by recurrent seizures, affects approximately 50 million people globally. In Europe, up to six million people are estimated to be living with the disease. Whilst treatment options have come a long way over the last few decades, clinical practice still shows significant unmet […] October 15, 2024 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 15 Oct 2024 Booster launches to treat neurodegenerative diseases with proteasome activation Discover Booster Therapeutics’ novel proteasome activation approach to neurodegenerative diseases as it launches with $15 million. October 15, 2024 - 6 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Best in Biotech 14 Oct 2024 Six biomimicry biotech companies harnessing nature’s wisdom to develop breakthrough drug candidates Find out more about six biomimicry companies harnessing nature’s wisdom to create drug candidates for the benefit of human health. October 14, 2024 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Podcast 11 Oct 2024Bispecific ADCs: the next generation of cancer treatments To talk about bispecific ADCs, and biotechs in Czechia, our conversation this week is with Radek Špíšek, CEO of SOTIO. October 11, 2024 Share WhatsApp Twitter Linkedin Email Listen Now Apple Music Spotify More
Expert Advice 11 Oct 2024 How to build your biotech company in 2024 (according to founders) Discover the insight successful biotech founders share with us to build your biotech company – from building your team to attracting funding. October 11, 2024 - 19 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 10 Oct 2024 Second biotech IPO boom of the year: what does it mean for the industry? Discover why biotech is experiencing a second IPO boom in 2024 and what it means for the broader industry. October 10, 2024 - 9 minutesmins - By Monica Karpinski Share WhatsApp Twitter Linkedin Email
Best in Biotech 10 Oct 2024 12 biotech unicorns revolutionizing the future of healthcare Take a closer look at 12 biotech unicorns, with a worth of more than $1 billion, that are trying to revolutionize the biopharma industry. October 10, 2024 - 11 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email